These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 1812353)

  • 1. Pitfalls of contrast-enhanced imaging in the nervous system.
    Brant-Zawadzki M
    Magn Reson Med; 1991 Dec; 22(2):243-8. PubMed ID: 1812353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gd DTPA: a review of clinical indications in central nervous system magnetic resonance imaging.
    Runge VM; Carollo BR; Wolf CR; Nelson KL; Gelblum DY
    Radiographics; 1989 Sep; 9(5):929-58. PubMed ID: 2678298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The enhancement effects of Gd-DTPA for cerebrospinal lesions-- comparison with conventional T2-weighted images].
    Mano I; Yoshida H; Kono T; Tsuchida T; Terao H; Iio M
    Rinsho Hoshasen; 1987 Dec; 32(13):1547-53. PubMed ID: 3448287
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of gadolinium-diethylenetriaminepentaacetic acid in the evaluation of the central nervous system.
    Runge VM; Gelblum DY
    Magn Reson Q; 1990 Apr; 6(2):85-107. PubMed ID: 2202425
    [No Abstract]   [Full Text] [Related]  

  • 5. Contrast-enhanced MRI of the central nervous system: comparison between gadodiamide injection and gadolinium-DTPA.
    Akeson P; Jonsson E; Haugen I; Holtås S
    Neuroradiology; 1995 Apr; 37(3):229-33. PubMed ID: 7603600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of dotarem (Gd-DOTA) versus magnevist (Gd-DTPA) in magnetic resonance imaging of the central nervous system.
    Oudkerk M; Sijens PE; Van Beek EJ; Kuijpers TJ
    Invest Radiol; 1995 Feb; 30(2):75-8. PubMed ID: 7782190
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Initial experiences with the use of gadolinium DTPA in infants and children under 2 years of age].
    Maas R; Grzyska U; Lausch N; Bücheler E
    Aktuelle Radiol; 1991 Jul; 1(4):196-200. PubMed ID: 1911897
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contrast-enhanced MR imaging of neurocutaneous melanosis.
    Rhodes RE; Friedman HS; Hatten HP; Hockenberger B; Oakes WJ; Tomita T
    AJNR Am J Neuroradiol; 1991; 12(2):380-2. PubMed ID: 1902050
    [No Abstract]   [Full Text] [Related]  

  • 9. Central nervous system lesions in pediatric patients: Gd-DTPA-enhanced MR imaging.
    Powers TA; Partain CL; Kessler RM; Freeman MW; Robertson RH; Wyatt SH; Whelan HT
    Radiology; 1988 Dec; 169(3):723-6. PubMed ID: 3055036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Contrast-enhanced MRI and contrast medium development].
    Iio M
    Nihon Rinsho; 1987 Jan; 45(1):28-32. PubMed ID: 3820681
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical experience with gadodiamide injection in magnetic resonance imaging of the central nervous system.
    Andrew E; Svaland M; Lundby B; Hugo F; LaFrance N
    Invest Radiol; 1994 Jun; 29 Suppl 2():S186-8. PubMed ID: 7928225
    [No Abstract]   [Full Text] [Related]  

  • 12. [Comparative studies of the tolerability of gadodiamide, dimeglumine gadopentetate and meglumine gadoterate in MRI tests of the central nervous system].
    Chanalet S; Masson B; Boyer L; Laffont J; Bruneton JN
    J Radiol; 1995 Jul; 76(7):417-21. PubMed ID: 7473375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Technical advances in magnetic resonance imaging.
    Bydder GM
    Curr Opin Neurol Neurosurg; 1992 Dec; 5(6):854-8. PubMed ID: 1467578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomised double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA).
    Brugières P; Gaston A; Degryse HR; Parizel PM; de Schepper AM; Berry I; Manelfe C; Le Bras F; Marsault C; Wichmann W
    Neuroradiology; 1994; 36(1):27-30. PubMed ID: 8107991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gd-DTPA as a contrast agent in CT.
    Bloem JL; Wondergem J
    Radiology; 1989 May; 171(2):578-9. PubMed ID: 2704827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indications for the use of Gd-DTPA in MRI of the central nervous system. Experiences in patients with cerebral and spinal diseases.
    Bauer WM; Fenzl G; Vogl T; Fink U; Lissner J
    Invest Radiol; 1988 Sep; 23 Suppl 1():S286-8. PubMed ID: 3198363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Basic principles of MR contrast.
    Nelson KL; Runge VM
    Top Magn Reson Imaging; 1995; 7(3):124-36. PubMed ID: 7654392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Magnetic resonance imaging of focal liver lesions. Comparison of the superparamagnetic iron oxide resovist versus gadolinium-DTPA in the same patient.
    Vogl TJ; Hammerstingl R; Schwarz W; Kümmel S; Müller PK; Balzer T; Lauten MJ; Balzer JO; Mack MG; Schimpfky C; Schrem H; Bechstein WO; Neuhaus P; Felix R
    Invest Radiol; 1996 Nov; 31(11):696-708. PubMed ID: 8915751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of the magnetic resonance contrast agent gadodiamide in the central nervous system. Results of a multicenter trial.
    Sze G; Brant-Zawadzki M; McNamara MT; Haughton VM; Kumar AJ; Maravilla KR; Aisen AM; Dreisbach JN; Bradley WG; Weinreb JC
    Invest Radiol; 1993 Mar; 28 Suppl 1():S49-55. PubMed ID: 8486504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancements in hepatobiliary imaging: the spectrum of gadolinium-ethoxybenzyl diethylenetriaminepentaacetic acid usages in hepatobiliary magnetic resonance imaging.
    Channual S; Pahwa A; Lu DS; Raman SS
    Abdom Radiol (NY); 2016 Sep; 41(9):1825-41. PubMed ID: 27225503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.